Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals

Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ:INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities.

The Inovio Pharmaceuticals Analyst: Geoff Meacham upgraded the rating for Inovio Pharmaceuticals from Underperform to Neutral while raising the price target from $8 to $10.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.